CLINICAL TRIALS PROFILE FOR PREVYMIS
✉ Email this page to a colleague
All Clinical Trials for prevymis
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Amy C. Sherman, MD | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Dana-Farber Cancer Institute | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for prevymis
Condition Name
Clinical Trial Locations for prevymis
Trials by Country
Clinical Trial Progress for prevymis
Clinical Trial Phase
Clinical Trial Sponsors for prevymis
Sponsor Name